ACLA Meets With FDA Head To Propose Inter-Agency Lab Regulation for Laboratory-Developed Tests
September 16, 2009
ACLA Meets With FDA Head To Propose Inter-Agency Lab Regulation for Laboratory-Developed Tests
During a webinar hosted this week by Genetic Alliance, Paul Radensky, a partner in the law firm McDermott Will & Emery, discussed FDA's regulation of diagnostic tests and noted that ACLA met with FDA Commissioner Margaret Hamburg to discuss a proposal for an inter-agency approach to regulating LDTs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Texas Congressman Drafts Bill to Keep Lab Test Oversight out of 'FDA's Lap,' Expand Authority of CMS
October 19, 2011 / Pharmacogenomics Reporter - FDA's Gutierrez Provides Additional Clarity Regarding Oversight of DTC Genomics Firms
May 19, 2010 / Pharmacogenomics Reporter - Q&A: CDRH's Gutierrez, Mansfield Discuss Ongoing Regulatory Efforts in Personalized Medicine
January 2, 2013 / Pharmacogenomics Reporter - Q&A: Lawyer Jeff Gibbs Discusses Implications of Veterinary Drug Case on FDA's LDT, RUO Guidances
January 18, 2012 / Pharmacogenomics Reporter - FDA/CMS Parallel Review of Medical Products Limited Only by Sponsors' Reluctance, CMS Official Says
December 7, 2011 / Pharmacogenomics Reporter